Mortality Reduced by 75%, page-18

The paradigm shift/change is coming fast. I say this in demonstration for my care for shorters....not!

It is only a matter of time. As I count myself as being a long-term holder now ~ 2years through thick and thin, I am persuaded that the wait is sqeeeezing with every announcement.

The information used for this conclusion with some bold added.....
Heart Attacks and Strokes (Single injection of MSB’s REXLEMESTROCEL-L)
“The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30 months following a single dose of rexlemestrocel-L”
“Patients who received rexlemestrocel-L had a 68% reduction in the rate of recurrent hospitalizations from non-fatal heart attacks or strokes compared with controls”

“The combination of the three pre-specified outcomes of cardiac death, heart attack or stroke into a single composite outcome - called the three-point Major Adverse Cardiovascular Event (MACE) is a well-established endpoint used by the United States Food and Drug Administration (FDA) to determine cardiovascular risk.”

Source: http://investorsmedia.mesoblast.com/static-files/7ac0b207-8219-49a0-b9a0-36030d30f50b


Chronic Lower Back Pain (Single injection of MSB’s REXLEMESTROCEL-L)
“Achievement of significant and durable reductions in CLBP through 24 months “
“Significant reduction in opioid use over 24 months in patients treated with MPC + HA, while increased opioid use occurred in saline controls”

“In the midst of the opioid epidemic in the United States, the Food and Drug Administration has prioritized a focus on new therapeutics that target both pain reduction and opioid avoidance, particularly for treating CLBP which accounts for 50% of opioid prescriptions.”

Source: http://investorsmedia.mesoblast.com/static-files/9ef49736-6ab2-4361-ad50-14f70a8f444d


Moderate/Severe COVID-19 ARDS (2 infusions of MSB’s REMESTEMCEL-L)
“Remestemcel-L reduced mortality by 46% through day 60 in the pre-specified population of 123 treated patients under age 65”
“Remestemcel-L reduced mortality through day 60 by 75% compared to controls in patients under 65 who received dexamethasone as part of their standard of care”

“Reduction in mortality in mechanically ventilated patients under 65 years old remains a critical unmet need since as many as 72% of currently hospitalized patients across the US with COVID-19 are in this age category.1” said Mesoblast Chief Executive, Silviu Itescu.

Source: http://investorsmedia.mesoblast.com/static-files/5e07904d-a452-46fb-977f-6b00cd79b992

The paradigm change cannot be halted imo...